Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?

Affiliations

¹ Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; ; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
² Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
³ Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy ;

Comment

Emanuele Zaffuto et al. Ann Transl Med. 2016 Aug.

. 2016 Aug;4(15):291.

doi: 10.21037/atm.2016.06.25.

¹ Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; ; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
² Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
³ Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy ;

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Buchler T, Bortlicek Z, Poprach A, Pavlik T, Veskrnova V, Honzirkova M, Zemanova M, Fiala O, Kubackova K, Slaby O, Svoboda M, Vyzula R, Dusek L, Melichar B; Czech Renal Cancer Cooperative Group. Buchler T, et al. Eur Urol. 2016 Sep;70(3):469-75. doi: 10.1016/j.eururo.2015.12.031. Epub 2015 Dec 30. Eur Urol. 2016. PMID: 26746623

1. Buchler T, Bortlicek Z, Poprach A, et al. Outcomes for patients with metastatic renal cell carcinoma achieving a complete response on targeted therapy: a registry-based analysis. Eur Urol 2016;70:469-75. - PubMed
1. Poprach A, Bortlíček Z, Büchler T, et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Med Oncol 2012;29:3314-20. 10.1007/s12032-012-0286-9 - DOI - PubMed
1. van den Brom RR, van Es SC, Leliveld AM, et al. Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. Cancer Treat Rev 2016;46:63-72. 10.1016/j.ctrv.2016.04.002 - DOI - PubMed
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. 10.3322/caac.21332 - DOI - PubMed
1. Hanzly M, Aboumohamed A, Yarlagadda N, et al. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. Urology 2014;83:1129-34. 10.1016/j.urology.2014.02.005 - DOI - PubMed